Association between the Lynch syndrome gene MSH2 and breast cancer susceptibility in a Canadian familial cancer registry

被引:24
作者
Goldberg, Mira [1 ]
Bell, Kathleen [1 ]
Aronson, Melyssa [2 ]
Semotiuk, Kara [2 ]
Pond, Greg [1 ]
Gallinger, Steven [3 ]
Zbuk, Kevin [1 ]
机构
[1] McMaster Univ, Dept Oncol, Hamilton, ON, Canada
[2] Mt Sinai Hosp, Zane Cohen Ctr Digest Dis, Toronto, ON, Canada
[3] Toronto Gen Hosp, Div Hepatobiliary & Pancreat Surg Oncol, Toronto, ON, Canada
关键词
NONPOLYPOSIS COLORECTAL-CANCER; MUTATION CARRIERS; EXTRACOLONIC CANCERS; ENDOMETRIAL CANCER; INTEGRAL TUMOR; RISKS; SPECTRUM; MLH1; CARCINOMA; PART;
D O I
10.1136/jmedgenet-2017-104542
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Background Previous studies assessing breast cancer risk in families with Lynch syndrome (LS) have yielded conflicting results. Furthermore, conclusions are limited by small sample size and few breast cancer outcomes. This study assesses breast cancer risk in a large prospectively followed LS cohort. Methods Pedigrees of 325 unrelated families with LS within the Familial Gastrointestinal Cancer Registry in Canada were examined for breast cancer diagnoses. Standardised incidence ratios (SIR) and lifetime cumulative incidence calculations were used to compare the incidence of breast cancer in mutation carriers with the general population. Results Forty-one mutation carriers diagnosed with breast cancer belonging to 34 unrelated families were identified. Mean age at diagnosis was 54 years. The mutation distribution among the LS patients with breast cancer was statistically different from those without breast cancer (p=0.015), reflecting the predominance of MSH2 mutations among affected patients (74%). Eighty-eight per cent of LS families with breast cancer met Amsterdam criteria, compared with 49% of LS families without breast cancer (p=0.03). Lifetime cumulative incidence of breast cancer in female MSH2 mutation carriers in our cohort was 22% (p<0.001). The SIR for breast cancer of female MSH2 mutation carriers in our cohort was 3.11 (95% CI 1.95 to 4.71). Conclusions An increased risk of breast cancer in MSH2 mutation carriers was demonstrated in a Canadian familial cancer registry. Women with breast cancer often had a personal and family history of multiple LS-related malignancies. These results suggest a potential role for intensified breast cancer surveillance among women with LS.
引用
收藏
页码:742 / 746
页数:5
相关论文
共 36 条
  • [1] Aarnio M, 1999, INT J CANCER, V81, P214, DOI 10.1002/(SICI)1097-0215(19990412)81:2<214::AID-IJC8>3.3.CO
  • [2] 2-C
  • [3] BRCA in breast cancer: ESMO Clinical Practice Guidelines
    Balmana, J.
    Diez, O.
    Rubio, I. T.
    Cardoso, F.
    [J]. ANNALS OF ONCOLOGY, 2011, 22 : vi31 - vi34
  • [4] Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations
    Barrow, E.
    Robinson, L.
    Alduaij, W.
    Shenton, A.
    Clancy, T.
    Lalloo, F.
    Hill, J.
    Evans, D. G.
    [J]. CLINICAL GENETICS, 2009, 75 (02) : 141 - 149
  • [5] Loss of Mismatch Repair Protein Expression in Breast Carcinoma in Patients with Lynch Syndrome: Report of Two Cases
    Beggs, Andrew D.
    Kousparos, George
    Hodgson, Shirley V.
    [J]. BREAST JOURNAL, 2013, 19 (02) : 193 - 195
  • [6] The extracolonic cancer spectrum in females with the common 'South African' hMLH1 c.C1528T mutation
    Blokhuis, Maria M.
    Goldberg, Paul A.
    Pietersen, G. Elize
    Algar, Ursula
    Vorster, A. Alvera
    Govender, Dhiren
    Ramesar, Raj S.
    [J]. FAMILIAL CANCER, 2008, 7 (03) : 191 - 198
  • [7] Male breast cancer in the hereditary nonpolyposis colorectal cancer syndrome
    Boyd, J
    Rhei, E
    Federici, MG
    Borgen, PI
    Watson, P
    Franklin, B
    Karr, B
    Lynch, J
    Lemon, SJ
    Lynch, HT
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 1999, 53 (01) : 87 - 91
  • [8] Evidence for Breast Cancer as an Integral Part of Lynch Syndrome
    Buerki, Nicole
    Gautier, Lucienne
    Kovac, Michal
    Marra, Giancarlo
    Buser, Mauro
    Mueller, Hansjakob
    Heinimann, Karl
    [J]. GENES CHROMOSOMES & CANCER, 2012, 51 (01) : 83 - 91
  • [9] Catts Z, 2011, HERED CANCER CLIN PR, V9, pP1
  • [10] Cancer Risks for MLH1 and MSH2 Mutation Carriers
    Dowty, James G.
    Win, Aung K.
    Buchanan, Daniel D.
    Lindor, Noralane M.
    Macrae, Finlay A.
    Clendenning, Mark
    Antill, Yoland C.
    Thibodeau, Stephen N.
    Casey, Graham
    Gallinger, Steve
    Le Marchand, Loic
    Newcomb, Polly A.
    Haile, Robert W.
    Young, Graeme P.
    James, Paul A.
    Giles, Graham G.
    Gunawardena, Shanaka R.
    Leggett, Barbara A.
    Gattas, Michael
    Boussioutas, Alex
    Ahnen, Dennis J.
    Baron, John A.
    Parry, Susan
    Goldblatt, Jack
    Young, Joanne P.
    Hopper, John L.
    Jenkins, Mark A.
    [J]. HUMAN MUTATION, 2013, 34 (03) : 490 - 497